Clinical Trial ResultsAfter 24 weeks of treatment with aficamten, 68% of patients demonstrated a complete hemodynamic response compared to 7% with placebo.
Drug EfficacyCytokinetics presented new responder analyses from the Phase 3 SEQUOIA-HCM trial of aficamten, showing significant improvements in clinically relevant outcomes.
SafetyThe safety profile of aficamten is viewed favorably, with no observed increases in rates of atrial fibrillation in key trials.